Cannabigerol, or CBG, is a non-psychoactive cannabinoid that has gained significant attention in recent years. While it may seem like a new discovery, its history is deeply intertwined with the foundational research into the cannabis plant itself. Often referred to as “the mother of all cannabinoids,” CBG’s unique role as a precursor to other major cannabinoids makes its story a critical part of the plant’s scientific legacy.
Discovery in the 1960s
The history of CBG begins in 1964, with the groundbreaking work of Israeli scientists Dr. Raphael Mechoulam and his colleagues, Yechiel Gaoni and Yuval Shvo. At the Weizmann Institute in Rehovot, their team became the first to successfully isolate and identify the chemical structures of numerous compounds from the cannabis plant. During this seminal research, they identified and characterized not only tetrahydrocannabinol (THC) and cannabidiol (CBD) but also cannabigerol (CBG). This discovery laid the groundwork for all subsequent cannabinoid research.
The researchers soon recognized a remarkable characteristic of CBG. They found that its acidic form, cannabigerolic acid (CBGA), is the foundational compound from which the cannabis plant biosynthesizes the other major cannabinoids, including THCA (the precursor to THC) and CBDA (the precursor to CBD). This unique function cemented CBG’s reputation as a “stem cell” or “mother” cannabinoid, a term that continues to be used today to describe its biological importance within the plant.
Early Research
Following its isolation, early studies on CBG confirmed that, unlike THC, it was non-psychoactive and did not produce an intoxicating “high.” Despite this early finding, scientific focus for decades remained overwhelmingly on THC due to its psychoactive effects and on CBD as a result of its promising therapeutic applications, particularly for epilepsy.
♦ Interested in trying high-quality CBD edibles for yourself? Check out the FGE shop♦
The legal and cultural status of cannabis in the mid-to-late 20th century also contributed to the slow pace of research. Widespread prohibition and a lack of funding for cannabis studies limited the exploration of many of the plant’s minor compounds, including CBG. While a handful of studies were conducted in the years following its discovery, the full potential and mechanisms of CBG were largely unexplored for over half a century.
Modern Cannabigerol Research
The landscape of cannabis science began to shift dramatically in the 21st century. The growing legalization of cannabis and hemp for medicinal and recreational use spurred a new wave of research. Scientists, no longer focused solely on THC and CBD, began to investigate the “minor” cannabinoids that had been overlooked for so long. CBG emerged as a prime candidate for further study.
Legal Status and the Future of CBG
The 2018 Farm Bill in the United States, which legalized industrial hemp and its derivatives with less than 0.3% THC, has been a major catalyst for the modern CBG market. This legal framework has allowed for the cultivation of high-CBG hemp strains and the creation of a diverse range of products, from tinctures and capsules to topicals.
Today, CBG is celebrated for its potential to provide therapeutic benefits without the psychoactive effects of THC. As a result, it has become a popular ingredient in wellness products aimed at promoting overall well-being, stress relief, and a balanced mood. While the history of CBG is a testament to the pioneering work of early cannabis researchers, its future is still being written as clinical trials and scientific studies continue to unlock its full potential.
